The biology of VEGF and its receptors
The DOI matches its Crossref record; 144 of the 144 references it cites were found in a registry or an index.
Abstract
Vascular endothelial growth factor (VEGF) is a key regulator of physiological angiogenesis during embryogenesis, skeletal growth and reproductive functions. VEGF has also been implicated in pathological angiogenesis associated with tumors, intraocular neovascular disorders and other conditions. The biological effects of VEGF are mediated by two receptor tyrosine kinases (RTKs), VEGFR-1 and VEGFR-2, which differ considerably in signaling properties. Non-signaling co-receptors also modulate VEGF RTK signaling. Currently, several VEGF inhibitors are undergoing clinical testing in several malignancies. VEGF inhibition is also being tested as a strategy for the prevention of angiogenesis, vascular leakage and visual loss in age-related macular degeneration.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It is well established that the formation of blood vessels occurs by angiogenesis and that vascular endothelial growth factor (VEGF) is a key molecule in promoting angiogenesis (Ferrara et al., 2003).”
From Molecular pathology of age-related macular degeneration (2009) · cites this paper as Ferrara et al., 2003
Citations
Cites
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180
Vascular Endothelial Growth Factor Is a Secreted Angiogenic Mitogen
Leung, D. W., Cachianes, G., Kuang, W.-J., Goeddel, D. V., & Ferrara, N. (1989) · Science · doi:10.1126/science.2479986 · Cited by 4,986 · cited 1×
“VEGF induces a potent angiogenic response in a variety of in vivo model”
BackgroundSelf-citationThe Biology of Vascular Endothelial Growth Factor
Ferrara, N., & Davis-Smyth, T. (1997) · Endocrine Reviews · doi:10.1210/edrv.18.1.0287 · Cited by 4,330
Self-citationMechanisms of angiogenesis and arteriogenesis
Carmeliet, P. (2000) · Nature Medicine · doi:10.1038/74651 · Cited by 4,162
Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele
Carmeliet, P., Ferreira, V., Breier, G., Pollefeyt, S., Kieckens, L., Gertsenstein, M., Fahrig, M., Vandenhoeck, A., Harpal, K., Eberhardt, C., et al. (1996) · Nature · doi:10.1038/380435a0 · Cited by 4,117
Maynard, S. E., Min, J.-Y., Merchan, J., Lim, K.-H., Li, J., Mondal, S., Libermann, T. A., Morgan, J. P., Sellke, F. W., Stillman, I. E., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17189 · Cited by 4,101
Tumor Cells Secrete a Vascular Permeability Factor That Promotes Accumulation of Ascites Fluid
Senger, D. R., Galli, S. J., Dvorak, A. M., Perruzzi, C. A., Harvey, V. S., & Dvorak, H. F. (1983) · Science · doi:10.1126/science.6823562 · Cited by 3,972 · cited 1×
“VEGF is known also as vascular permeability factor, based on its ability to induce vascular leakag”
BackgroundFailure of blood-island formation and vasculogenesis in Flk-1-deficient mice
Shalaby, F., Rossant, J., Yamaguchi, T. P., Gertsenstein, M., Wu, X.-F., Breitman, M. L., & Schuh, A. C. (1995) · Nature · doi:10.1038/376062a0 · Cited by 3,931
Aiello, L. P., Avery, R. L., Arrigg, P. G., Keyt, B. A., Jampel, H. D., Shah, S. T., Pasquale, L. R., Thieme, H., Iwamoto, M. A., Park, J. E., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199412013312203 · Cited by 3,793
Self-citationVascular-specific growth factors and blood vessel formation
Yancopoulos, G. D., Davis, S., Gale, N. W., Rudge, J. S., Wiegand, S. J., & Holash, J. (2000) · Nature · doi:10.1038/35025215 · Cited by 3,699 · cited 1×
“Many molecules have been implicated as positive regulators of angiogenesis, including acidic fibroblast growth factor (FGF), basic FGF, transforming growth factor (TGF)-α, TGF-β, hepatocyte growth factor (HGF, or scatter factor), tumor necrosis factor-α, angiogenin, interleukin (IL)-8 and the angiopoietin”
Background
Research works printed but not linked: 3
- Presta, L.G. et al. Humanization of an anti-VEGF monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 57, 4593–4599 (1997).
- Prewett, M. et al. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis. Cancer Res. 59, 5209–5218 (1999).
- Yang, J.C. et al. A randomized trial of bevacizumab (anti-VEGF antibody) in metastatic renal cancer. N. Engl. J. Med. (in the press).
Cited by
Items 201–300 of 1,056
Oxidative Stress, Inflammation, and Disease
Chatterjee, S. (2016) · Oxidative Stress and Biomaterials · doi:10.1016/b978-0-12-803269-5.00002-4 · Cited by 314
Targeted therapies in breast cancer: New challenges to fight against resistance
Masoud, V., & Pagès, G. (2017) · World Journal of Clinical Oncology · doi:10.5306/wjco.v8.i2.120 · Cited by 357
Koontongkaew, S. (2013) · Journal of Cancer · doi:10.7150/jca.5112 · Cited by 361
“These include VEFG-A, placental growth factor, VEGF-B, VEGF-C, VEGF-D, and VEGF-F [37].”
BackgroundLichtenberger, B. M., Tan, P. K., Niederleithner, H., Ferrara, N., Petzelbauer, P., & Sibilia, M. (2010) · Cell · doi:10.1016/j.cell.2009.12.046 · Cited by 358
“VEGF is a key regulator of vasculogenesis and angiogenesis and binds to two related RTKs, VEGFR1/Flt1 and VEGFR2/KDR/Flk1, both of which are primarily expressed on vascular endothelial cells (ECs), and to neuropilins (Nrp), a family of coreceptors known to enhance VEGFR signaling (Ferrara et al., 2003; Takahashi and S…”
InfluentialSelf-citationUp-regulation of the Notch ligand Delta-like 4 inhibits VEGF-induced endothelial cell function
Williams, C. K., Li, J.-L., Murga, M., Harris, A. L., & Tosato, G. (2006) · Blood · doi:10.1182/blood-2005-03-1000 · Cited by 360
“50 We also found that Dll4 down-regulates endothelial cell expression of NRP1, which functions as a coreceptor for members of the VEGF-A family, enhancing VEGFR2 activity.”
BackgroundChaiworapongsa, T., Romero, R., Espinoza, J., Bujold, E., Mee Kim, Y., Gonçalves, L. F., Gomez, R., & Edwin, S. (2004) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2004.03.043 · Cited by 368
Clinical pharmacokinetics of bevacizumab in patients with solid tumors
Lu, J.-F., Bruno, R., Eppler, S., Novotny, W., Lum, B., & Gaudreault, J. (2008) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-007-0664-8 · Cited by 350
“Vascular endothelial growth factor, a diffusible glycoprotein produced by normal and neoplastic cells, is an important regulator of physiologic and pathologic angiogenesis [6].”
BackgroundResistance to Anti-Angiogenic Therapy in Cancer—Alterations to Anti-VEGF Pathway
Itatani, Y., Kawada, K., Yamamoto, T., & Sakai, Y. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19041232 · Cited by 346
“VEGFA is a growth/survival factor for endothelial cells and binds to two receptor tyrosine kinases (RTKs), VEGF receptor (VEGFR) 1 and 2 [6].”
BackgroundTargeting angiogenesis: progress with anti-VEGF treatment with large molecules
Grothey, A., & Galanis, E. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.110 · Cited by 356
Ehrbar, M., Djonov, V. G., Schnell, C., Tschanz, S. A., Martiny-Baron, G., Schenk, U., Wood, J., Burri, P. H., Hubbell, J. A., & Zisch, A. H. (2004) · Circulation Research · doi:10.1161/01.res.0000126411.29641.08 · Cited by 357
Enhanced osteoporotic bone regeneration by strontium-substituted calcium silicate bioactive ceramics
Lin, K., Xia, L., Li, H., Jiang, X., Pan, H., Xu, Y., Lu, W. W., Zhang, Z., & Chang, J. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.09.056 · Cited by 356
Vascular endothelial growth factor stimulates skeletal muscle regeneration in Vivo
Arsic, N., Zacchigna, S., Zentilin, L., Ramirez-Correa, G., Pattarini, L., Salvi, A., Sinagra, G., & Giacca, M. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.08.007 · Cited by 349
“The precise role of the other receptors in the angiogenic process still remains poorly understood; VEGFR-1 has been proposed as a decoy receptor, limiting the access of free VEGF to VEGFR-2, while VEGFR-3 seems to have a fundamental role on the lymphatic endothelium mainly through interaction with VEGF-C and VEGF-D (f…”
BackgroundNucleic Acid Aptamers: Clinical Applications and Promising New Horizons
Ni, X., Castanares, M., Mukherjee, A., & Lupold, S. E. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711797189600 · Cited by 349
“VEGF165 is a homodimeric protein of two 165 amino acid polypeptide chains and it is critical in blood vessel formation and in causing the increased permeability involved in vision loss associated with neovascular AMD [28].”
BackgroundInfluentialAvery, R. L., Castellarin, A. A., Steinle, N. C., Dhoot, D. S., Pieramici, D. J., See, R., Couvillion, S., Nasir, M. A., Rabena, M. D., Maia, M., et al. (2017) · Retina · doi:10.1097/iae.0000000000001493 · Cited by 352
VEGFR1 signaling in retinal angiogenesis and microinflammation
Uemura, A., Fruttiger, M., D'Amore, P. A., De Falco, S., Joussen, A. M., Sennlaub, F., Brunck, L. R., Johnson, K. T., Lambrou, G. N., Rittenhouse, K. D., et al. (2021) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2021.100954 · Cited by 354
“Accordingly, the review begins by introducing the current biology of the VEGFR1 itself and in context with VEGFR2, Abbreviations AMD Age-related macular degeneration BRB Blood–retina barrier BRVO Branch retinal vein occlusion CCL2 CC chemokine ligand 2 CNV Choroidal neovascularization CRVO Central retinal vein occlusi…”
BackgroundInfluentialChaiworapongsa, T., Romero, R., Kim, Y. M., Kim, G. J., Kim, M. R., Espinoza, J., Bujold, E., Gonçalves, L., Gomez, R., Edwin, S., et al. (2005) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.1080/14767050400028816 · Cited by 359
“VEGF can promote endothelial cell prolifera- tion, migration [31], and survival [32], and exerts its biologic effects through two high-affinity tyrosine kinase receptors: VEGFR-1 (VEGF receptor-1 or flt- 1 or fms-like tyrosine kinase-1) and VEGFR-2 (VEGF receptor-2 or KDR/Flk-1 or kinase domain receptor).”
BackgroundInfluentialAlternative Vascularization Mechanisms in Cancer
Döme, B., Hendrix, M. J. C., Paku, S., Tóvári, J., & Tímár, J. (2007) · The American Journal of Pathology · doi:10.2353/ajpath.2007.060302 · Cited by 359
Regulation and biological activities of the autotaxin–LPA axis
van Meeteren, L. A., & Moolenaar, W. H. (2007) · Progress in Lipid Research · doi:10.1016/j.plipres.2007.02.001 · Cited by 353
Regulation of the Pulmonary Circulation in the Fetus and Newborn
Gao, Y., & Raj, J. U. (2010) · Physiological Reviews · doi:10.1152/physrev.00032.2009 · Cited by 345
VEGF-Induced Vascular Permeability Is Mediated by FAK
Chen, X. L., Nam, J.-O., Jean, C., Lawson, C., Walsh, C. T., Goka, E., Lim, S.-T., Tomar, A., Tancioni, I., Uryu, S., et al. (2012) · Developmental Cell · doi:10.1016/j.devcel.2011.11.002 · Cited by 341
“Vascular endothelial growth factor (VEGF) promotes vascular leak, angiogenesis, and the tyrosine phosphorylation of VE-cadherin and b-catenin (Dejana et al., 2008; Ferrara et al., 2003; Lilien and Balsamo, 2005).”
The axonal attractant Netrin-1 is an angiogenic factor
Park, K. W., Crouse, D., Lee, M., Karnik, S. K., Sorensen, L. K., Murphy, K. J., Kuo, C. J., & Li, D. Y. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405984101 · Cited by 333
Angiogenesis in Gliomas: Biology and Molecular Pathophysiology
Fischer, I., Gagner, J., Law, M., Newcomb, E. W., & Zagzag, D. (2005) · Brain Pathology · doi:10.1111/j.1750-3639.2005.tb00115.x · Cited by 350
“The VEGF isoforms exert their function through three cognate VEGF receptor ty- rosine kinases: VEGFR-1/Flt-1, VEGFR-2 Flk-1/KDR, and VEGFR-3 and 2 neuropilins receptors, NRP-1 and NRP-2 (48, 49, 61, 123, 183).”
BackgroundInfluentialGlioblastoma multiforme: State of the art and future therapeutics
Harter, D., Wilson, T., & Karajannis, M. (2014) · Surgical Neurology International · doi:10.4103/2152-7806.132138 · Cited by 327
“[168,199] Vascular endothelial growth factor (VEGF), a critical mediator of angiogenesis, is highly overexpressed in GBM.[31,62,68,69,165,184] VEGF has been correlated with clinical outcomes, including time to recurrence and survival.”
BackgroundAnti-angiogenesis therapy in cancer: Current challenges and future perspectives
Shojaei, F. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.03.008 · Cited by 348
Xie, C., Wan, X., Quan, H., Zheng, M., Fu, L., Li, Y., & Lou, L. (2018) · Cancer Science · doi:10.1111/cas.13536 · Cited by 348
“Vascular endothelial growth factor is capable of regulating angiogenic processes, including endothelial cell migration and proliferation, neovascular survival, capillary tube formation and permeability, among others.13 Vascular endothelial growth factor exerts its biological effects by activating RTK, VEGFR1, VEGFR2,…”
BackgroundBlocking Neuropilin-2 Function Inhibits Tumor Cell Metastasis
Caunt, M., Mak, J., Liang, W.-C., Stawicki, S., Pan, Q., Tong, R. K., Kowalski, J., Ho, C., Reslan, H. B., Ross, J., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.01.029 · Cited by 343
Self-citationDynamic contrast-enhanced MRI in clinical trials of antivascular therapies
O'Connor, J. P. B., Jackson, A., Parker, G. J. M., Roberts, C., & Jayson, G. C. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.2 · Cited by 348
“For trials with antivascular agents targeting VEGF ligand and VEGF receptor 2 (VEGFR-2), K trans might be a reasonable choice of biomarker as VEGF blockage is believed to reduce vascular permeabilit”
BackgroundQian, F., Engst, S., Yamaguchi, K., Yu, P., Won, K.-A., Mock, L., Lou, T., Tan, J., Li, C., Tam, D., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4889 · Cited by 350
“models inhibits tumor angiogenesis and tumor growth (36, 37).”
BackgroundRamalingam, S. S., Dahlberg, S. E., Langer, C. J., Gray, R., Belani, C. P., Brahmer, J. R., Sandler, A. B., Schiller, J. H., & Johnson, D. H. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.1144 · Cited by 348
VEGF-A Links Angiogenesis and Inflammation in Inflammatory Bowel Disease Pathogenesis
Scaldaferri, F., Vetrano, S., Sans, M., Arena, V., Straface, G., Stigliano, E., Repici, A., Sturm, A., Malesci, A., Panes, J., et al. (2009) · Gastroenterology · doi:10.1053/j.gastro.2008.09.064 · Cited by 340
VEGF-A: a critical regulator of blood vessel growth
Ferrara, N. (2009) · European Cytokine Network · doi:10.1684/ecn.2009.0170 · Cited by 327
“VEGF belongs to a gene family that also includes VEGF-B, C, D, E, and placenta growth factor [20-23].”
BackgroundSelf-citationRole of Bv8 in neutrophil-dependent angiogenesis in a transgenic model of cancer progression
Shojaei, F., Singh, M., Thompson, J. D., & Ferrara, N. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0712185105 · Cited by 334
“Vascular endothelial growth factor (VEGF)-A is one of the most important regulators of physiological and/or pathological angiogenesis (2).”
BackgroundSelf-citationEssential role of Flk-1 (VEGF receptor 2) tyrosine residue 1173 in vasculogenesis in mice
Sakurai, Y., Ohgimoto, K., Kataoka, Y., Yoshida, N., & Shibuya, M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0404984102 · Cited by 330
The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications
Podar, K., & Anderson, K. C. (2005) · Blood · doi:10.1182/blood-2004-07-2909 · Cited by 343
Mechanical loading, cartilage degradation, and arthritis
Sun, H. B. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05808.x · Cited by 335
Hyperoxia causes angiopoietin 2–mediated acute lung injury and necrotic cell death
Bhandari, V., Choo-Wing, R., Lee, C. G., Zhu, Z., Nedrelow, J. H., Chupp, G. L., Zhang, X., Matthay, M. A., Ware, L. B., Homer, R. J., et al. (2006) · Nature Medicine · doi:10.1038/nm1494 · Cited by 337
“Angiogenesis and vascular remodeling are key events in fundamental physiological processes, including growth and development, wound healing, organ regeneration, inflammation and reproductio”
Targeting angiogenesis in oncology, ophthalmology and beyond
Cao, Y., Langer, R., & Ferrara, N. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00671-z · Cited by 315
Self-citationVan der Veldt, A. A. M., Lubberink, M., Bahce, I., Walraven, M., de Boer, M. P., Greuter, H. N. J. M., Hendrikse, N. H., Eriksson, J., Windhorst, A. D., Postmus, P. E., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2011.11.023 · Cited by 337
“Vascular endothelial growth factor (VEGF), which is overexpressed in many human malignancies, is a key regulator of tumor angiogenesis, inducing proliferation, differentiation, and migration of endothelial cells (Ferrara et al., 2003).”
BackgroundIncorporation of Pazopanib in Maintenance Therapy of Ovarian Cancer
du Bois, A., Floquet, A., Kim, J.-W., Rau, J., del Campo, J. M., Friedlander, M., Pignata, S., Fujiwara, K., Vergote, I., Colombo, N., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.7348 · Cited by 328
Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy
Qin, S., Li, A., Yi, M., Yu, S., Zhang, M., & Wu, K. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0718-5 · Cited by 324
“Certain well-known pro-angiogenic factors include vascular endothelial growth factor (VEGF) [5], angiopoietin (ANGPT) [6], basic fibroblast growth factor (bFGF) [7], and platelet-derived growth factor (PDGF) [8], while endogenous anti-angiogenic factors encompass endostatin [9], angiostatin [10], and so on.”
BackgroundDual or multi-targeting inhibitors: The next generation anticancer agents
Raghavendra, N. M., Pingili, D., Kadasi, S., Mettu, A., & Prasad, S. V. U. M. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.10.021 · Cited by 333
Chen, T. T., Luque, A., Lee, S., Anderson, S. M., Segura, T., & Iruela-Arispe, M. L. (2010) · Journal of Cell Biology · doi:10.1083/jcb.200906044 · Cited by 320
Azad, N. S., Posadas, E. M., Kwitkowski, V. E., Steinberg, S. M., Jain, L., Annunziata, C. M., Minasian, L., Sarosy, G., Kotz, H. L., Premkumar, A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.10.8332 · Cited by 332
“We hypothesized that sorafenib and bevacizumab would act in series in the VEGF pathway (Fig 1), inhibiting ligand-receptor interaction, receptor activation, and propagation of downstream signals that both produce VEGF and increase endothelial cell proliferation, survival, and vascular remodeling.(11) Here we report th…”
Semenza, G. L. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21523 · Cited by 317
“VEGF is produced early in the angiogenic cascade and is responsible for initial activation of endothelial cells [Carmeliet, 2003; Ferrara et al., 2003].”
BackgroundHong, Y., Lange‐Asschenfeldt, B., Velasco, P., Hirakawa, S., Kunstfeld, R., Brown, L. F., Bohlen, P., Senger, D. R., & Detmar, M. (2004) · The FASEB Journal · doi:10.1096/fj.03-1179fje · Cited by 323
VHL and HIF signalling in renal cell carcinogenesis
Baldewijns, M. M., van Vlodrop, I. J., Vermeulen, P. B., Soetekouw, P. M., van Engeland, M., & de Bruïne, A. P. (2010) · The Journal of Pathology · doi:10.1002/path.2689 · Cited by 316
“VEGF-A is the prototypical member of a family of factors that also consists of VEGF-B, VEGF-C, VEGF-D, and placental growth factor (PLGF), which selectively bind differentially to VEGF receptors 1, 2, and 3, and neuropilin with different specificities [63].”
BackgroundRosenstein, J. M., Krum, J. M., & Ruhrberg, C. (2010) · Organogenesis · doi:10.4161/org.6.2.11687 · Cited by 314
Pathways mediating VEGF-independent tumor angiogenesis
Ferrara, N. (2010) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2009.11.003 · Cited by 313
“that also includes VEGF-B, VEGF-C, VEGF-D and PlGF [1,13,39].”
BackgroundInfluentialSelf-citationSupramolecular nanostructures that mimic VEGF as a strategy for ischemic tissue repair
Webber, M. J., Tongers, J., Newcomb, C. J., Marquardt, K.-T., Bauersachs, J., Losordo, D. W., & Stupp, S. I. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1016546108 · Cited by 324
Tumor-associated neutrophils and neutrophil-targeted cancer therapies
Que, H., Fu, Q., Lan, T., Tian, X., & Wei, X. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188762 · Cited by 312
Dual-function injectable angiogenic biomaterial for the repair of brain tissue following stroke
Nih, L. R., Gojgini, S., Carmichael, S. T., & Segura, T. (2018) · Nature Materials · doi:10.1038/s41563-018-0083-8 · Cited by 323
Regulation of scar formation by vascular endothelial growth factor
Wilgus, T. A., Ferreira, A. M., Oberyszyn, T. M., Bergdall, V. K., & DiPietro, L. A. (2008) · Laboratory Investigation · doi:10.1038/labinvest.2008.36 · Cited by 319
“VEGF binds two high-affinity tyrosine kinase receptors to exert its effects on vascular endothelial cells, vascular endothelial growth factor receptor-1 (VEGFR-1) (flt-1) and VEGFR-2 (flk-1 or KDR).(15)”
BackgroundEngineering vascularized and innervated bone biomaterials for improved skeletal tissue regeneration
Marrella, A., Lee, T. Y., Lee, D. H., Karuthedom, S., Syla, D., Chawla, A., Khademhosseini, A., & Jang, H. L. (2018) · Materials Today · doi:10.1016/j.mattod.2017.10.005 · Cited by 311
DePrimo, S. E., Bello, C. L., Smeraglia, J., Baum, C. M., Spinella, D., Rini, B. I., Michaelson, M. D., & Motzer, R. J. (2007) · Journal of Translational Medicine · doi:10.1186/1479-5876-5-32 · Cited by 318
Pike, D. B., Cai, S., Pomraning, K. R., Firpo, M. A., Fisher, R. J., Shu, X. Z., Prestwich, G. D., & Peattie, R. A. (2006) · Biomaterials · doi:10.1016/j.biomaterials.2006.05.018 · Cited by 316
“It also tends to encourage endothelial cell mitosis and vascular permeability to a greater extent than VEGFR-1 [19].”
BackgroundInfluentialVascularization—The Conduit to Viable Engineered Tissues
Kaully, T., Kaufman-Francis, K., Lesman, A., & Levenberg, S. (2009) · Tissue Engineering Part B: Reviews · doi:10.1089/ten.teb.2008.0193 · Cited by 317
“11 Several models of angiogenesis have been developed to investigate its mechanism under well-defined in vitro conditions.”
Ophthalmic drug discovery: novel targets and mechanisms for retinal diseases and glaucoma
Zhang, K., Zhang, L., & Weinreb, R. N. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3745 · Cited by 316
Significance of immunohistochemistry in breast cancer
Zaha, D. C. (2014) · World Journal of Clinical Oncology · doi:10.5306/wjco.v5.i3.382 · Cited by 277
Roberts, N., Kloos, B., Cassella, M., Podgrabinska, S., Persaud, K., Wu, Y., Pytowski, B., & Skobe, M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-1843 · Cited by 315
“Vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 play a central role in tumor angiogenesis, and agents that block VEGF signaling pathways have shown promising results in clinical trials (5).”
BackgroundTear cytokine and chemokine analysis and clinical correlations in evaporative-type dry eye disease.
Enríquez‐de‐Salamanca, A., Castellanos, E., Stern, M. E., Fernández, I., Carreño, E., García‐Vázquez, C., Herreras, J. M., & Calonge, M. (2010) · PubMed Central · Cited by 425
The Role of Inflammation in Cancer: Mechanisms of Tumor Initiation, Progression, and Metastasis
Nishida, A., & Andoh, A. (2025) · Cells · doi:10.3390/cells14070488 · Cited by 270
“Among these mediators, VEGF-A is the most potent driver of hypoxia-induced angiogenesis [45,47].”
Pratheeshkumar, P., Budhraja, A., Son, Y.-O., Wang, X., Zhang, Z., Ding, S., Wang, L., Hitron, A., Lee, J.-C., Xu, M., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047516 · Cited by 307
“Activation of VEGFR-2 contributes to phosphorylation of multiple downstream signals including ERK, JNK, PI3K, AKT, P70S6K and p38MAPK that subsequently promote proliferation, migration, and tube formation of endothelial cells [7].”
Inflammatory Markers in Dysmenorrhea and Therapeutic Options
Barcikowska, Z., Rajkowska-Labon, E., Grzybowska, M. E., Hansdorfer-Korzon, R., & Zorena, K. (2020) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17041191 · Cited by 269
“It is known that VEGF is the strongest factor involved in the embryonic development, menstrual cycle, and in ovarian endometriomas [45].”
BackgroundAdjuvant Treatment of Colorectal Cancer
Wolpin, B. M., Meyerhardt, J. A., Mamon, H. J., & Mayer, R. J. (2007) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.57.3.168 · Cited by 306
Amant, F., Mirza, M. R., & Creutzberg, C. L. (2012) · International Journal of Gynecology & Obstetrics · doi:10.1016/s0020-7292(12)60024-1 · Cited by 309
“Overexpression of VEGF results in increased endothelial cell proliferation, decreased apoptosis, and increased fenestration of endothelial cells [70,72].”
Kunstfeld, R., Hirakawa, S., Hong, Y.-K., Schacht, V., Lange-Asschenfeldt, B., Velasco, P., Lin, C., Fiebiger, E., Wei, X., Wu, Y., et al. (2004) · Blood · doi:10.1182/blood-2003-08-2964 · Cited by 311
Angiogenic Role of LYVE-1–Positive Macrophages in Adipose Tissue
Cho, C.-H., Jun Koh, Y., Han, J., Sung, H.-K., Jong Lee, H., Morisada, T., Schwendener, R. A., Brekken, R. A., Kang, G., Oike, Y., et al. (2007) · Circulation Research · doi:10.1161/01.res.0000259564.92792.93 · Cited by 309
The impact of VEGF on cancer metastasis and systemic disease
Yang, Y., & Cao, Y. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.03.011 · Cited by 286
Hypoxia-driven pathways in bone development, regeneration and disease
Maes, C., Carmeliet, G., & Schipani, E. (2012) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2012.36 · Cited by 300
Wijelath, E. S., Rahman, S., Namekata, M., Murray, J., Nishimura, T., Mostafavi-Pour, Z., Patel, Y., Suda, Y., Humphries, M. J., & Sobel, M. (2006) · Circulation Research · doi:10.1161/01.res.0000246849.17887.66 · Cited by 293
Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma
Iwamoto, F. M., Abrey, L. E., Beal, K., Gutin, P. H., Rosenblum, M. K., Reuter, V. E., DeAngelis, L. M., & Lassman, A. B. (2009) · Neurology · doi:10.1212/wnl.0b013e3181bc0184 · Cited by 305
Identification of molecular apocrine breast tumours by microarray analysis
Farmer, P., Bonnefoi, H., Becette, V, Tubiana-Hulin, M., Fumoleau, P., Larsimont, D., MacGrogan, G., Bergh, J., Cameron, D., Goldstein, D., et al. (2005) · Breast Cancer Research · doi:10.1186/bcr1122 · Cited by 307
Chiu, L. L. Y., & Radisic, M. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2009.09.039 · Cited by 302
Role of angiogenesis and angiogenic factors in acute and chronic wound healing
Kumar, P., Kumar, S., Udupa, E. P., Kumar, U., Rao, P., & Honnegowda, T. (2015) · Plastic and Aesthetic Research · doi:10.4103/2347-9264.165438 · Cited by 290
The role of vascular endothelial growth factor in ossification
Yang, Y.-Q., Tan, Y.-Y., Wong, R., Wenden, A., Zhang, L.-K., & Rabie, A. B. M. (2012) · International Journal of Oral Science · doi:10.1038/ijos.2012.33 · Cited by 295
Stupack, D. G., & Cheresh, D. A. (2004) · Current Topics in Developmental Biology · doi:10.1016/s0070-2153(04)64009-9 · Cited by 295
DVORAK, H. F. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01361.x · Cited by 296
Matulonis, U. A., Berlin, S., Ivy, P., Tyburski, K., Krasner, C., Zarwan, C., Berkenblit, A., Campos, S., Horowitz, N., Cannistra, S. A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.2777 · Cited by 302
Epoxy metabolites of docosahexaenoic acid (DHA) inhibit angiogenesis, tumor growth, and metastasis
Zhang, G., Panigrahy, D., Mahakian, L. M., Yang, J., Liu, J.-Y., Stephen Lee, K. S., Wettersten, H. I., Ulu, A., Hu, X., Tam, S., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1304321110 · Cited by 293
“VEGFR2 is the most important VEGF receptor, mediating almost all known cellular responses of VEGF and is the therapeutic target of numerous angiogenesis inhibitors on the market (30).”
BackgroundInfluentialLaMontagne, K., Littlewood-Evans, A., Schnell, C., O'Reilly, T., Wyder, L., Sanchez, T., Probst, B., Butler, J., Wood, A., Liau, G., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2001 · Cited by 295
Favier, B., Alam, A., Barron, P., Bonnin, J., Laboudie, P., Fons, P., Mandron, M., Herault, J.-P., Neufeld, G., Savi, P., et al. (2006) · Blood · doi:10.1182/blood-2005-11-4447 · Cited by 292
VEGF‐null cells require PDGFR α signaling‐mediated stromal fibroblast recruitment for tumorigenesis
Dong, J., Grunstein, J., Tejada, M., Peale, F., Frantz, G., Liang, W., Bai, W., Yu, L., Kowalski, J., Liang, X., et al. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600289 · Cited by 295
“Sections 5mm thick were processed for in situ hybridization (Ferrara et al, 2003a).”
BackgroundMethodSelf-citationEma, M., Takahashi, S., & Rossant, J. (2006) · Blood · doi:10.1182/blood-2005-05-1970 · Cited by 295
D'Andrea, L. D., Iaccarino, G., Fattorusso, R., Sorriento, D., Carannante, C., Capasso, D., Trimarco, B., & Pedone, C. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0505047102 · Cited by 290
Angiogenesis and vascular function in the ovary
Robinson, R. S., Woad, K. J., Hammond, A. J., Laird, M., Hunter, M. G., & Mann, G. E. (2009) · Reproduction · doi:10.1530/rep-09-0283 · Cited by 290
“For example, there are five VEGFA isoforms, which have varying biochemical and biological properties (Ferrara et al. 2003).”
BackgroundSasaki, M., Knobbe, C. B., Itsumi, M., Elia, A. J., Harris, I. S., Chio, I. I. C., Cairns, R. A., McCracken, S., Wakeham, A., Haight, J., et al. (2012) · Genes & Development · doi:10.1101/gad.198200.112 · Cited by 296
“One important proangiogenic factor is Vegf, which is an endothelial cell mitogen that activates these cells to release proteases, proliferate, migrate, and form new vascular structures (Ferrara et al. 2003).”
BackgroundA Cell-Based Model Exhibiting Branching and Anastomosis during Tumor-Induced Angiogenesis
Bauer, A. L., Jackson, T. L., & Jiang, Y. (2007) · Biophysical Journal · doi:10.1529/biophysj.106.101501 · Cited by 297
Savin, I. A., Zenkova, M. A., & Sen’kova, A. V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314959 · Cited by 279
Therapeutic advances of targeting receptor tyrosine kinases in cancer
Tomuleasa, C., Tigu, A.-B., Munteanu, R., Moldovan, C.-S., Kegyes, D., Onaciu, A., Gulei, D., Ghiaur, G., Einsele, H., & Croce, C. M. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01899-w · Cited by 260
Castells, M., Thibault, B., Delord, J.-P., & Couderc, B. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms13089545 · Cited by 285
“During the angiogenesis process, VEGF is secreted by several cells including endothelial cells and tumor cells [19].”
BackgroundGranados-Romero, J. J., Valderrama-Treviño, A. I., Contreras-Flores, E. H., Barrera-Mera, B., Herrera Enríquez, M., Uriarte-Ruíz, K., Ceballos-Villalba, J. C., Estrada-Mata, A. G., Alvarado Rodríguez, C., & Arauz-Peña, G. (2017) · International Journal of Research in Medical Sciences · doi:10.18203/2320-6012.ijrms20174914 · Cited by 279
“Currently, the role of an antibody variant called Bevacizumab (Avastin) approved by the US Food and Drug Administration (FDA) has been studied by lowering vascular endothelial growth factor (VEGF), the main angiogenesis regulator, produced by normal and neoplastic cells 50 Preclinical trials have shown that a human mo…”
BackgroundTargeting VEGF and Its Receptors for the Treatment of Osteoarthritis and Associated Pain
Hamilton, J. L., Nagao, M., Levine, B. R., Chen, D., Olsen, B. R., & Im, H.-J. (2016) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2828 · Cited by 287
“(9,10) Murine counterparts of human VEGF include VEGF120, VEGF164, VEGF188, and VEGF205.”
BackgroundInfluentialPhage display screening of therapeutic peptide for cancer targeting and therapy
Saw, P. E., & Song, E.-W. (2019) · Protein & Cell · doi:10.1007/s13238-019-0639-7 · Cited by 279
Unraveling the Role of Angiogenesis in Cancer Ecosystems
Zuazo-Gaztelu, I., & Casanovas, O. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00248 · Cited by 275
“The polarization of the moving endothelial cells eventually constitutes the vessel lumen, forming an immature blood vessel (24).”
BackgroundHepatic Stellate Cells Secrete Angiopoietin 1 That Induces Angiogenesis in Liver Fibrosis
Taura, K., De Minicis, S., Seki, E., Hatano, E., Iwaisako, K., Osterreicher, C. H., Kodama, Y., Miura, K., Ikai, I., Uemoto, S., et al. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.07.065 · Cited by 286
Li, H., & Chang, J. (2013) · Acta Biomaterialia · doi:10.1016/j.actbio.2013.02.014 · Cited by 290
“It is well known that VEGF is an angiogenic growth factor that regulates all downstream signaling and expression of related genes involved in the critical steps of the angiogenic process [19,21,23,41].”
BackgroundBielenberg, D. R., Hida, Y., Shimizu, A., Kaipainen, A., Kreuter, M., Kim, C. C., & Klagsbrun, M. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200421378 · Cited by 286
“For example, VEGF kinase inhibitors and soluble VEGFRs block VEGFR signaling needed for angiogenesis (43).”
Narrative Review: The Systemic Capillary Leak Syndrome
Druey, K. M., & Greipp, P. R. (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-153-2-201007200-00005 · Cited by 281
“The endothelial dysfunction seen in SCLS also typifies a diverse group of disorders, including diabetic retinopathy (87), lupus nephritis (88), and infection with malaria or Ebola or Marburg viruses (89, 90).”
BackgroundNew roles for VEGF in nervous tissue?beyond blood vessels
ROSENSTEIN, J. (2004) · Experimental Neurology · doi:10.1016/j.expneurol.2004.01.022 · Cited by 282
“Magic Chloro”: Profound Effects of the Chlorine Atom in Drug Discovery
Chiodi, D., & Ishihara, Y. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c02015 · Cited by 263
Metadata
- Authors
- Ferrara, N., Gerber, H.-P., & LeCouter, J.
- Affiliations
- Genentech (US)
- Corresponding author
- Ferrara, Napoleone
- Venue
- Nature Medicine
- Published
- 2003-06-01
- Volume
- 9
- Issue
- 6
- Pages
- 669-676
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2000292756
- Cited by
- 9,591
- References
- 144
- Citations by year
- 2026: 154 · 2025: 270 · 2024: 292 · 2023: 317 · 2022: 336 · 2021: 386 · 2020: 379 · 2019: 403 · 2018: 384 · 2017: 466 · 2016: 460 · 2015: 485 · 2014: 551 · 2013: 527 · 2012: 580
- FWCI
- 28.12
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › Lymphatic System and Diseases
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Keywords
- vascular endothelial growth factor, VEGF receptors, VEGFR1, VEGFR2, receptor tyrosine kinase signaling, angiogenesis, pathological angiogenesis, tumor angiogenesis, intraocular neovascularization, VEGF inhibitors, age-related macular degeneration, vascular leakage, embryonic development
- MeSH terms
- Animals, Clinical Trials as Topic, Endothelium, Vascular, Growth Substances, Humans, Lymphokines, Neovascularization, Pathologic, Oxygen, Signal Transduction, Endothelial Growth Factors, Neovascularization, Physiologic, Protein Isoforms, Intercellular Signaling Peptides and Proteins, Receptors, Vascular Endothelial Growth Factor, Vascular Endothelial Growth Factors, Vascular Endothelial Growth Factor A
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.